Table 1.
Demographic and baseline characteristics of the matched cohort by age group.
| ≤45 years (n = 177) | 46–55 years (n = 177) | 56–64 years (n = 177) | ≥65 years (n = 177) | p values | |
|---|---|---|---|---|---|
| Demographics | |||||
| Sex, male | 123 (70%) | 120 (68%) | 119 (67%) | 122 (69%) | 0.9671 |
| Age, years |
39 (6) |
51 (3) |
60 (3) |
69 (3) |
<0.0001 |
| Clinic | |||||
| T2DM | 65 (37%) | 71 (40%) | 72 (41%) | 70 (40%) | 0.8762 |
| Dyslipidemia | 85 (48%) | 88 (50%) | 93 (53%) | 90 (51%) | 0.8570 |
| Hypertension | 102 (58%) | 108 (61%) | 111 (63%) | 108 (61%) | 0.7985 |
| BMI, kg/m2 | 33.11 (5.96) | 33.01 (5.61) | 32.93 (4.61) | 32.84 (5.22) | 0.9714 |
| Obesity |
123 (70%) |
121 (68%) |
128 (72%) |
119 (67%) |
0.7555 |
| Histology | |||||
| MASLD | 177 (100%) | 177 (100%) | 177 (100%) | 177 (100%) | n.a. |
| MASH | 123 (70%) | 125 (71%) | 124 (70%) | 124 (70%) | 0.9967 |
| At-risk MASH | 91 (51%) | 91 (51%) | 91 (51%) | 91 (51%) | 1.0 |
| F | 1.93 (1.14) | 1.89 (1.13) | 1.9 (1.12) | 1.9 (1.14) | 0.9889 |
| F, 0/1/2/3/4 | 23 (13.0%)/43 (24.3%)/45 (25.4%)/56 (31.6%)/10 (5.6%) | 21 (11.9%)/50 (28.2%)/43 (24.3%)/53 (29.9%)/10 (5.6%) | 19 (10.7%)/53 (29.9%)/41 (23.2%)/54 (30.5%)/10 (5.6%) | 22 (12.4%)/49 (27.7%)/41 (23.2%)/55 (31.1%)/10 (5.6%) | n.a. |
| MAS | 4.29 (1.74) | 4.3 (1.68) | 4.29 (1.76) | 4.31 (1.71) | 0.9991 |
| MAS, 1–2/3–4/5–6/7–8 | 27 (15.3%)/68 (38.4%)/62 (35%)/20 (11.3%) | 28 (15.8%)/64 (36.2%)/68 (38.4%)/17 (9.6%) | 30 (16.9%)/62 (35.0%)/61 (34.5%)/24 (13.6%) | 29 (16.4%)/63 (35.6%)/65 (36.7%)/20 (11.3%) | n.a. |
| Steatosis | 2.02 (0.79) | 2.04 (0.78) | 2.04 (0.78) | 2.04 (0.78) | 0.9962 |
| Steatosis score, 1/2/3 | 53 (29.9%)/67 (37.9%)/57 (32.2%) | 50 (28.2%)/70 (39.5%)/57 (32.2%) | 50 (28.2%)/70 (39.5%)/57 (32.2%) | 50 (28.2%)/70 (39.5%)/57 (32.2%) | n.a. |
| Ballooning | 1.05 (0.79) | 1.04 (0.79) | 1.05 (0.79) | 1.05 (0.79) | 0.9998 |
| Ballooning score, 0/1/2 | 51 (28.8%)/67 (37.9%)/59 (33.3%) | 51 (28.8%)/68 (38.4%)/58 (32.8%) | 51 (28.8%)/67 (37.9%)/59 (33.3%) | 51 (28.8%)/67 (37.9%)/59 (33.3%) | n.a. |
| Lobular inflammation | 1.23 (0.66) | 1.22 (0.62) | 1.21 (0.63) | 1.23 (0.63) | 0.9949 |
| Lobular inflammation score, 0/1/2/3 | 18 (10.2%)/106 (59.9%)/48 (27.1%)/5 (2.8%) | 16 (9%)/109 (61.6%)/49 (27.7%)/3 (1.7%) | 17 (9.6%)/109 (61.6%)/48 (27.1%)/3 (1.7%) | 16 (9.0%)/108 (61.0%)/50 (28.2%)/3 (1.7%) | n.a. |
Matched cohort, n = 708. At-risk MASH was defined as MASH with MAS ≥4 and F ≥2. Values are expressed as n (%) or mean (SD). p values were calculated by using either Chi square tests for proportion comparisons or Kruskal-Wallis tests for numerical features.
MAS, MASLD activity score; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated liver disease; n.a., not applicable; T2DM, type 2 diabetes mellitus.